This report provides exclusive insights into the COVID-19 impact on the Hypertension Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Hypertension Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Hypertension Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on
hypertension drugs market provides an in-depth analysis of segments and
sub-segments in the global as well as regional hypertension drugs market. The
study also highlights the impact of drivers, restraints, and macro indicators
on the global and regional hypertension drugs market over the short term as
well as long term. The report is a comprehensive presentation of trends,
forecast and dollar values of the global hypertension drugs market. According to
the report, the global hypertension drugs market is projected to grow at a CAGR
of 3.5% over the forecast period of 2019-2025.
Hypertension affects about 75 million Americans, one out of three
adults. It is the leading cause of cardiovascular disease, resulting in about
1,000 deaths per day. The current paradigm of managing hypertension is
increasing the demand for hypertension drugs over the globe. The overall class
of antihypertensive agents lowers blood pressure, although the mechanisms of
action vary greatly. Among them, the thiazide diuretics, the ACE inhibitors,
the calcium channel blockers, the beta-blockers, and the angiotensin II
receptor antagonists or ARBs are the most important and most widely used.
The incessantly increasing occurrences of hypertension and growing
awareness regarding hypertension management are the major driving factors for
the growth of the hypertension drugs market. Uncontrolled high blood pressure
raises the risk of heart disease and stroke, which are leading causes of death
in the United States. The stressful lifestyle, unhealthy diet, physical
inactivity, cigarette smoking, and high intake of alcohol are augmenting the
prevalence of hypertension among individuals that are resulting in the growth of
the hypertension drugs market. In addition, rising income levels coupled with enhanced
medical infrastructure are propelling the growth of the market. Furthermore,
with age, there is an increase in blood pressure in the general population.
Therefore, the growing elderly population is also anticipated to aid the growth
of the hypertension drugs market. However, side effects associated with the
continuous use of these drugs is likely to restrain the growth of the
hypertension drugs market. Moreover, the expansion of market coverage by
multinationals is expected to bring new and emerging opportunities in the
hypertension drugs market.
Among the regions, North America holds the dominant share in the
global hypertension market. The U.S is the key revenue contributor in the North
America hypertension market. In addition, high blood pressure affects a huge
population in the U.S. Furthermore, high per capita expenditure on healthcare,
high disposable income, and reformation in the healthcare system such as
reimbursement offerings are contributing to an enormous revenue in the North
America hypertension market. Moreover, Asia-Pacific is anticipated to grow at a
significant pace over the forecast period owing to increasing occurrences of
hypertension, changing dietary habits and sedentary lifestyle trends in
emerging markets such as China and India.
The report on global hypertension drugs market covers segments
such as analysis type, therapy type, and distribution channels. On the basis of
analysis type, the sub-markets include systemic hypertension drugs, and
pulmonary hypertension drugs. On the basis of therapy type, the sub-markets
include calcium channel blockers, diuretics, beta blockers vasodilators,
angiotensin converting enzyme inhibitor, alpha blockers, angiotensin receptor
blockers, and renin inhibitors. On the basis of distribution channels, the
sub-markets include hospital pharmacy, retail pharmacy, and online pharmacy.
The report provides profiles of the companies in the market such
as Pfizer, Inc., AstraZeneca plc, Novartis AG, Daiichi Sankyo Company, Ltd.,
United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services,
Inc., Boehringer Engelheim GmbH, Takeda Pharmaceutical Company, and Bayer AG.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of hypertension
drugs market. Moreover, the study highlights current market trends and provides
forecast from 2019-2025. We also have highlighted future trends in the market
that will affect the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players.